Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1756)	7/26/2006 5:01:31 PM
From: tuck	Read Replies (2) \| Respond to of 1784

>>LA JOLLA, Calif. (AP) -- Stratagene Corp., a maker of life science research and testing products, said Wednesday a jury found that the company infringed a patent held by Invitrogen Corp., a maker of genomics research equipment. The case was handed back to a federal district court in Texas after Invitrogen won an appeal in October. The jury found that some Stratagene products infringed an Invitrogen patent involving a process allowing bacteria to absorb foreign DNA, or become "competent." As a result, Invitrogen was awarded a 15 percent royalty rate on sales of the infringing products, or about $7.8 million in damages, from 1997 and 2004. The jury did not award lost profits to Invitrogen because Stratagene used a non-infringing manufacturing process. Invitrogen had been seeking $32 million in lost profits. Representatives at Invitrogen, Carlsbad, Calif., were not available for immediate comment. The company first sued Stratagene in March 2001. Stratagene said it has the option to appeal the verdict. Shares of Invitrogen rose 48 cents to $65 in premarket activity on the INET electronic exchange.<< Another appeal? Hmm. I've lost track of Stratagene's legal issues. It is still duking it out with TWTI, I believe, but would have to check the 10-K. Might be worth a look. The company seems to execute reasonably well, but these legal issues seem to keep a lid on it. Cheers, Tuck